STOCK TITAN

IN8bio (NASDAQ: INAB) director awarded options on 22,000 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IN8BIO director Greenwood Luba received a stock option grant for 22,000 shares of common stock. The option has an exercise price of $1.58 per share and expires on May 9, 2036. One-twelfth of the shares vest monthly starting June 9, 2026, with full vesting at the next annual stockholders’ meeting if service continues.

Positive

  • None.

Negative

  • None.
Insider Greenwood Luba
Role null
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 22,000 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 22,000 shares (Direct, null)
Footnotes (1)
  1. [object Object]
Options granted 22,000 options Stock Option grant to director Greenwood Luba
Exercise price $1.58 per share Exercise price of granted stock options
Expiration date May 9, 2036 Option expiration for 22,000-share grant
Shares underlying options 22,000 shares Common stock underlying the option grant
Post-transaction derivative holdings 22,000 options Total options held after this grant
Vesting start date June 9, 2026 First monthly vesting date for the option
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 1.5800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to the option shall vest in equal monthly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-05-09T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
Common Stock financial
"underlying_security_title: Common Stock"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Greenwood Luba

(Last)(First)(Middle)
C/O IN8BIO, INC.
350 5TH AVE. SUITE 5330

(Street)
NEW YORK NEW YORK 10118

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IN8BIO, INC. [ INAB ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$1.5805/09/2026A22,000 (1)05/09/2036Common Stock22,000$022,000D
Explanation of Responses:
1. One twelfth (1/12th) of the shares subject to the option shall vest in equal monthly installments commencing on June 9, 2026; provided, however, that the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
/s/ William Ho, Attorney-in-Fact05/12/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did IN8BIO (INAB) director Greenwood Luba report?

Greenwood Luba reported receiving a stock option grant for 22,000 shares of IN8BIO common stock. This is a compensation-related award, not an open-market purchase or sale, and reflects additional potential equity exposure tied to future company performance.

What is the exercise price of Greenwood Luba’s IN8BIO stock options?

The granted stock options have an exercise price of $1.58 per share. This means Luba can buy IN8BIO common stock at $1.58 once options vest and are exercised, if that is below the market price at exercise time.

How do Greenwood Luba’s IN8BIO stock options vest?

One-twelfth of the 22,000 options vest in equal monthly installments starting June 9, 2026. The options will in any case be fully vested on the date of IN8BIO’s next annual stockholders’ meeting, assuming Luba continues providing service through each vesting date.

When do Greenwood Luba’s IN8BIO stock options expire?

The stock options granted to Greenwood Luba expire on May 9, 2036. If not exercised by that expiration date, the right to purchase the underlying 22,000 shares at the $1.58 exercise price will lapse and become worthless.

Is Greenwood Luba’s Form 4 transaction a buy or a sale of IN8BIO shares?

The Form 4 reports an option grant, classified as an acquisition, not an open-market buy or sale. Luba received 22,000 stock options as a grant with no cash paid, and no IN8BIO common shares were sold in this transaction.